Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2)-targeted therapies are highly effective at preventing breast cancer recurrence but are associated with cardiotoxicity in some patients, and minimal data are available regarding racial disparities in the incidence of this toxicity. The authors conducted a retrospective study to analyze the association of black or white race with treatment-induced cardiotoxicity and incomplete therapy among patients with HER2-positive early breast cancer.

Methods

Women with HER2-positive, stage I through III breast cancer who initiated (neo)adjuvant HER2-targeted therapy (trastuzumab with or without pertuzumab) from January 2005 to March 2015 at the authors' institution were eligible. We analyzed differences in the incidence of cardiot

SUBMITTER: Litvak A 

PROVIDER: S-EPMC5910274 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature